Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

First Posted Date
2021-04-12
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
92
Registration Number
NCT04840602
Locations
🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

and more 101 locations

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

First Posted Date
2021-03-26
Last Posted Date
2024-10-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT04817241
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

and more 4 locations

Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Phase 1
Completed
Conditions
Renal Impairment
Renal Disease
Interventions
Drug: Venetoclax
First Posted Date
2021-03-23
Last Posted Date
2022-09-16
Lead Sponsor
AbbVie
Target Recruit Count
12
Registration Number
NCT04810598
Locations
🇺🇸

Orlando Clinical Research Ctr /ID# 224922, Orlando, Florida, United States

🇺🇸

Acpru /Id# 243398, Grayslake, Illinois, United States

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

First Posted Date
2021-03-23
Last Posted Date
2024-10-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT04812548
Locations
🇪🇸

Novartis Investigative Site, Barcelona, Catalunya, Spain

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

First Posted Date
2021-03-17
Last Posted Date
2024-03-18
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
172
Registration Number
NCT04801797
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

First Posted Date
2021-03-15
Last Posted Date
2024-11-21
Lead Sponsor
University of Washington
Target Recruit Count
20
Registration Number
NCT04797767
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2021-03-10
Last Posted Date
2024-07-11
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
50
Registration Number
NCT04790903
Locations
🇫🇷

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France

🇫🇷

CHU Montpellier - Saint ELOI, Montpellier, France

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 17 locations

Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

Phase 4
Not yet recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Venetoclax
First Posted Date
2021-03-10
Last Posted Date
2023-10-03
Lead Sponsor
Paolo Ghia
Target Recruit Count
30
Registration Number
NCT04790045

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

First Posted Date
2021-03-03
Last Posted Date
2024-04-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
258
Registration Number
NCT04778397
Locations
🇦🇺

Fiona Stanley Hospital, Murdoch, Western Australia, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 153 locations

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

First Posted Date
2021-03-03
Last Posted Date
2024-10-08
Lead Sponsor
Gilead Sciences
Target Recruit Count
54
Registration Number
NCT04778410
Locations
🇺🇸

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy